Conexeu Sciences is trading 6.11% lower in pre-market at $3.44, with no specific overnight catalyst identified.
- This compares with its October 6 close of $3.66; shares gained 17.31% during that session.
- On October 6, the company said scaled-up material batches met specifications and its planned FDA 510(k) submission remains on track for Q1 2027.
- That update does not clearly explain the pre-market decline; the provided market moves are modest.